{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:44:08Z","timestamp":1791776648715,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation","doi-asserted-by":"crossref","award":["82572634"],"award-info":[{"award-number":["82572634"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Innovation of Science and Technology, Fujian Province","award":["2025Y9156"],"award-info":[{"award-number":["2025Y9156"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02142-2","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:05:01Z","timestamp":1775045101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a risk prediction model and management strategy for red blood cell irregular antibodies a retrospective cohort study of 521 patients"],"prefix":"10.1007","volume":"26","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaopei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbiao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"19","key":"2142_CR1","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2016.9185","volume":"316","author":"JL Carson","year":"2016","unstructured":"Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025\u201335.","journal-title":"JAMA"},{"issue":"17","key":"2142_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2018-08-833962","volume":"133","author":"CA Tormey","year":"2019","unstructured":"Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133(17):1821.","journal-title":"Blood"},{"issue":"10061","key":"2142_CR3","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/S0140-6736(15)01313-6","volume":"388","author":"M Delaney","year":"2016","unstructured":"Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825.","journal-title":"Lancet"},{"issue":"2","key":"2142_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/j.1537-2995.2006.00708.x","volume":"46","author":"H Schonewille","year":"2006","unstructured":"Schonewille H, Van De Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006;46(2):250\u20136.","journal-title":"Transfusion"},{"issue":"4","key":"2142_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/trf.15718","volume":"60","author":"RG Hauser","year":"2020","unstructured":"Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena-Merle R, Spencer BR, et al. The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion. 2020;60(4):831\u20139.","journal-title":"Transfusion"},{"issue":"2","key":"2142_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/vox.12864","volume":"115","author":"Z Ye","year":"2020","unstructured":"Ye Z, Wolf LA, Mettman D, Plapp FV. Risk of RBC alloimmunization in multiple myeloma patients treated by daratumumab. Vox Sang. 2020;115(2):207\u201312.","journal-title":"Vox Sang"},{"issue":"6","key":"2142_CR7","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood-2008-03-146415","volume":"112","author":"JM Higgins","year":"2008","unstructured":"Higgins JM, Sloan SR. Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood. 2008;112(6):2546.","journal-title":"Blood"},{"issue":"3","key":"2142_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/cancers15030975","volume":"15","author":"L Smith","year":"2023","unstructured":"Smith L, Carmichael J, Cook G, Shinkins B, Neal RD. Development and internal validation of a risk prediction model to identify myeloma based on routine blood tests: a case-control study. Cancers. 2023;15(3):975.","journal-title":"Cancers"},{"issue":"9","key":"2142_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","volume":"98","author":"KG Moons","year":"2012","unstructured":"Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683.","journal-title":"Heart"},{"key":"2142_CR10","doi-asserted-by":"publisher","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","volume":"10","author":"L Yamamoto","year":"2021","unstructured":"Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the immune system against multiple myeloma: challenges and opportunities. Front Oncol. 2021;10:606368.","journal-title":"Front Oncol"},{"issue":"4","key":"2142_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cll.2021.07.011","volume":"41","author":"T Schneider","year":"2021","unstructured":"Schneider T, Jackups R Jr. Transfusion medicine informatics: a review of current practice and a glimpse into the future. Clin Lab Med. 2021;41(4):713\u201325.","journal-title":"Clin Lab Med"},{"issue":"3","key":"2142_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1537-2995.2008.02014.x","volume":"49","author":"CA Tormey","year":"2009","unstructured":"Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49(3):505\u201312.","journal-title":"Transfusion"},{"key":"2142_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490623","author":"ST Chou","year":"2013","unstructured":"Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013. https:\/\/doi.org\/10.1182\/blood-2013-03-490623.","journal-title":"Blood"},{"key":"2142_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/tme.13096","author":"P Pakthipa","year":"2024","unstructured":"Pakthipa P, Nattarat L, Phandee W, et al. Risk factors for red blood cell alloimmunization in patients with hematologic malignancy. Transfus Med. 2024. https:\/\/doi.org\/10.1111\/tme.13096.","journal-title":"Transfus Med"},{"key":"2142_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133213","author":"B Cirino","year":"2021","unstructured":"Cirino B, Francesco M, Enrica Antonia M, et al. Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13133213.","journal-title":"Cancers (Basel)"},{"key":"2142_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069","author":"CI Chapuy","year":"2015","unstructured":"Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015. https:\/\/doi.org\/10.1111\/trf.13069.","journal-title":"Transfusion"},{"issue":"6","key":"2142_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2003-09-3015","volume":"103","author":"C Hoppe","year":"2004","unstructured":"Hoppe C, Klitz W, Cheng S, Apple R, Steiner L, Robles L, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood. 2004;103(6):2391\u20136.","journal-title":"Blood"},{"key":"2142_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100593","author":"EK Storch","year":"2019","unstructured":"Storch EK, Custer BS, Jacobs MR, et al. Review of current transfusion therapy and blood banking practices. Blood Rev. 2019. https:\/\/doi.org\/10.1016\/j.blre.2019.100593.","journal-title":"Blood Rev"},{"key":"2142_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.05.004","author":"P Alexander","year":"2009","unstructured":"Alexander P, Alvaro A, Elizabeth S, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009. https:\/\/doi.org\/10.1016\/j.it.2009.05.004.","journal-title":"Trends Immunol"},{"key":"2142_CR20","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.007","author":"KJ Moise","year":"2005","unstructured":"Moise KJ. Red blood cell alloimmunization in pregnancy. Semin Hematol. 2005. https:\/\/doi.org\/10.1053\/j.seminhematol.2005.04.007.","journal-title":"Semin Hematol"},{"key":"2142_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995","author":"JM Koelewijn","year":"2008","unstructured":"Koelewijn JM, Vrijkotte TG, Van Der Schoot CE, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion. 2008. https:\/\/doi.org\/10.1111\/j.1537-2995.","journal-title":"Transfusion"},{"issue":"3","key":"2142_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ajog.2015.08.068","volume":"214","author":"LD Pacheco","year":"2016","unstructured":"Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. Am J Obstet Gynecol. 2016;214(3):340\u20134.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2142_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1537-2995.2009.02456.x","volume":"50","author":"G Daniels","year":"2010","unstructured":"Daniels G, Reid ME. Blood groups: the past 50 years. Transfusion. 2010;50(2):281\u20139.","journal-title":"Transfusion"},{"issue":"5","key":"2142_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-3148.2002.00399.x","volume":"12","author":"G Daniels","year":"2002","unstructured":"Daniels G, Poole J, De Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. Transfus Med. 2002;12(5):287\u201395.","journal-title":"Transfus Med"},{"key":"2142_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015. https:\/\/doi.org\/10.1136\/bmj.g7594.","journal-title":"BMJ"},{"issue":"12","key":"2142_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/ajh.24908","volume":"92","author":"D Narbey","year":"2017","unstructured":"Narbey D, Habibi A, Chadebech P, Mekontso-Dessap A, Khellaf M, Leli\u00e8vre JD, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340\u20138.","journal-title":"Am J Hematol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02142-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:25:20Z","timestamp":1776219920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02142-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2142"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02142-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"\u2018Not Applicable\u2019 as no human study is involved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol was approved by the Ethics Committee of [The First Affiliated Hospital, Fujian Medical University] (Approval No.: MTCA, FMU.ECFAH[2015]084\u20133), In this study, upon admission, patients are informed in the \u201cAdmission Notice\u201d that their medical case information and health data will be utilized for scientific research. Written consent was obtained from each patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"217"}}